Dr. Anna Sureda | EBMT 2018 | Summary of the transplant algorithm in Hodgkin lymphoma

• Dr Sureda gives a summary of the transplant algorithm in lymphoma highlighting that autologous stem cell transplant (ASCT) is still a standard of care in relapsed / refractory Hodgkin lymphoma.
• She explains that the results of ASCT have been improved by PET-adapted strategies. New drugs such as brentuximab vedotin and checkpoint inhibitors can improve disease status before transplant.
• Finally, she notes that allogeneic transplant is an option for those who relapse after ASCT but this will become less frequent as new drugs are more successful.

44th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT), 18-21 March 2018, Lisbon, Portugal

Dr Anna Sureda, Catalan Institute of Oncology, Barcelona, ES